Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer
Authors:
- 1 January 2020
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 16 (1) , e37-e55
Abstract
PURPOSE: To understand genetic testing use and decision making among patients with high genetic risk. MATERIALS AND METHODS: A survey of breast cancer survivors was administered online by a hereditary cancer nonprofit organization, Facing Our Risk of Cancer Empowered, from October 2017 to March 2018. RESULTS: Of 1,322 respondents, 46% had breast cancer at age < 45 years, 61% had a first-degree relative with cancer, and 84% underwent genetic testing, of whom 56% had a risk-associated pathogenic variant. Most (86%; 95% CI, 84% to 88%) tested respondents were very satisfied with their testing decision, versus 34% (95% CI, 27% to 41%) of untested respondents. Factors that encouraged testing included relatives’ cancer risk (75%; 95% CI, 73% to 78%), clinicians’ recommendations (68%; 95% CI, 66% to 71%), and potential treatment implications (67%; 95% CI, 64% to 69%). Factors that discouraged testing included insurance concerns (14%; 95% CI, 12% to 16%), cost (14%; 95% CI, 12% to 16%), and discrimination (9%; 95% CI, 7% to 11%). Thirty-nine percent (95% CI, 36% to 41%) recalled hearing from a clinician that genetic discrimination is illegal. Respondents often recalled clinicians informing them about inheritance patterns (65%; 95% CI, 62% to 67%), surgical implications (65%; 95% CI, 63% to 68%), and other cancer risks (66%; 95% CI, 63% to 68%) but less often that results could have potential implications for clinical trial eligibility (38%; 95% CI, 36% to 42%) or targeted therapies (14%; 95% CI, 12% to 16%). Patients who had genetic counseling were twice as likely to recall clinicians informing them about all queried topics. Results did not vary by diagnosis year. CONCLUSION: Among patients with high genetic risk, clinicians’ recommendations, potential treatment implications, and protections against discrimination were motivating factors to undergo genetic testing, but fewer than half recalled clinicians providing all this information, and this did not improve over time. Clinicians influence testing decisions and should inform patients about legal protections and treatment implications.Keywords
This publication has 32 references indexed in Scilit:
- Gene Patents and Personalized Cancer Care: Impact of the Myriad Case on Clinical OncologyJournal of Clinical Oncology, 2013
- A Statewide Survey of Practitioners to Assess Knowledge and Clinical Practices Regarding Hereditary Breast and Ovarian CancerGenetic Testing and Molecular Biomarkers, 2013
- Barriers and Facilitators for Utilization of Genetic Counseling and Risk Assessment Services in Young Female Breast Cancer SurvivorsJournal of Cancer Epidemiology, 2012
- Barriers and facilitators to BRCA genetic counseling among at‐risk Latinas in New York CityPsycho-Oncology, 2012
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast CancerJournal of Clinical Oncology, 2010
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersNew England Journal of Medicine, 2009
- Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patientsBreast Cancer Research and Treatment, 2008
- Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriersFamilial Cancer, 2007
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005